Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Palmoplantar Epidermal Differentiation Disorders - Pachyonychia Congenita (pEDD-PC): KRT6A-pEDD-PC, KRT6B-pEDD-PC, KRT6C-pEDD-PC, KRT16-pEDD-PC and KRT17-pEDD-PC

NCT07893483 is registered in ClinicalTrials.gov with Orvida Pharma (formerly Kamari Pharma) as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07893483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Palmoplantar Epidermal Differentiation Disorders - Pachyonychia Congenita (pEDD-PC): KRT6A-pEDD-PC, KRT6B-pEDD-PC, KRT6C-pEDD-PC, KRT16-pEDD-PC and KRT17-pEDD-PC
Lead sponsor
Orvida Pharma (formerly Kamari Pharma)
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
November 30, 2027
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 1 arm.

  • Treatment arm ExperimentalKM-023

Primary endpoints

Registered primary outcome measures; 6 primary.

  • To assess the safety of repeated doses of oral KM-023 in individuals with PC. Day 112

    The incidence, seriousness, relationship, and outcome of TEAEs.

  • To assess the safety of repeated doses of oral KM-023 in individuals with PC. Day 112

    Change from baseline in clinical laboratory parameters.

  • To assess the safety of repeated doses of oral KM-023 in individuals with PC. Day 112

    Change from baseline in vital signs.

  • To assess the safety of repeated doses of oral KM-023 in individuals with PC. Day 112

    Change from baseline in 12-lead ECG

  • To assess the safety of repeated doses of oral KM-023 in individuals with PC. Day 112

    Change from baseline in physical examination.

+1 more primary endpoint

Lead sponsor's other trials

Orvida Pharma (formerly Kamari Pharma), most recent start first.